Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Other financing activities (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Other financing activities for 4 consecutive years, with -$90000.0 as the latest value for Q4 2025.

  • Quarterly Other financing activities rose 51.35% to -$90000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$337000.0 through Dec 2025, down 101.8% year-over-year, with the annual reading at -$337000.0 for FY2025, 101.8% down from the prior year.
  • Other financing activities hit -$90000.0 in Q4 2025 for Taysha Gene Therapies, up from -$285000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.1 million in Q4 2022 to a low of -$640000.0 in Q3 2023.
  • Historically, Other financing activities has averaged -$28846.2 across 4 years, with a median of -$80000.0 in 2025.
  • Biggest YoY gain for Other financing activities was 266.09% in 2023; the steepest drop was 1222.81% in 2023.
  • Year by year, Other financing activities stood at $1.1 million in 2022, then plummeted by 97.75% to $24000.0 in 2023, then plummeted by 870.83% to -$185000.0 in 2024, then surged by 51.35% to -$90000.0 in 2025.
  • Business Quant data shows Other financing activities for TSHA at -$90000.0 in Q4 2025, -$285000.0 in Q3 2025, and $118000.0 in Q2 2025.